A Study in Healthy Humans to Assess the Relative Bioavailability of One Fixed-dose Combination Tablet Empagliflozin/Metformin Versus Jardiance® Tablet and Glifage® Tablet Administered Together

NCT05083949 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: FDC 12.5mg empagliflozin/850mg metformin
DRUG: Empagliflozin
DRUG: Glifage®

Sponsor

Boehringer Ingelheim